BiVictriX Therapeutics PLC (GB:BVX) has released an update.
BiVictriX Therapeutics PLC reports a pivotal year with substantial progress in its lead cancer therapeutic, BVX001, targeting Acute Myeloid Leukaemia and advancing towards clinical studies. The company has also expanded its proprietary Bi-Cygni® discovery platform, strengthened its intellectual property portfolio, and is preparing two antibody drug conjugates for clinic readiness by 2026. Despite consistent R&D investments and a steady cash position, the company closed the year with a £2.5 million loss, matching the previous year’s figures.
For further insights into GB:BVX stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
